MX2015001508A - El uso de antitrombina en la oxigenacion por membrana extracorporea. - Google Patents
El uso de antitrombina en la oxigenacion por membrana extracorporea.Info
- Publication number
- MX2015001508A MX2015001508A MX2015001508A MX2015001508A MX2015001508A MX 2015001508 A MX2015001508 A MX 2015001508A MX 2015001508 A MX2015001508 A MX 2015001508A MX 2015001508 A MX2015001508 A MX 2015001508A MX 2015001508 A MX2015001508 A MX 2015001508A
- Authority
- MX
- Mexico
- Prior art keywords
- antithrombin
- extracorporeal membrane
- membrane oxygenation
- oxygenation
- extracorporeal
- Prior art date
Links
- 239000004019 antithrombin Substances 0.000 title abstract 3
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679345P | 2012-08-03 | 2012-08-03 | |
| PCT/US2013/053365 WO2014022748A1 (en) | 2012-08-03 | 2013-08-02 | The use of antithrombin in extracorporeal membrane oxygenation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015001508A true MX2015001508A (es) | 2015-04-08 |
Family
ID=50028554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015001508A MX2015001508A (es) | 2012-08-03 | 2013-08-02 | El uso de antitrombina en la oxigenacion por membrana extracorporea. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9511087B2 (https=) |
| EP (1) | EP2879697A4 (https=) |
| JP (1) | JP6389172B2 (https=) |
| KR (1) | KR20150039201A (https=) |
| CN (1) | CN104884080A (https=) |
| AR (1) | AR091977A1 (https=) |
| AU (1) | AU2013296240B2 (https=) |
| BR (1) | BR112015002321A2 (https=) |
| CA (1) | CA2879763C (https=) |
| IL (1) | IL236776A0 (https=) |
| MX (1) | MX2015001508A (https=) |
| TW (1) | TW201425332A (https=) |
| WO (1) | WO2014022748A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2811526T3 (es) | 2010-12-30 | 2021-03-12 | Lab Francais Du Fractionnement | Glicoles como agentes de inactivación de patógenos |
| EP2879697A4 (en) | 2012-08-03 | 2016-01-20 | Lfb Usa Inc | USE OF ANTITHROMBIN IN OXYGENATION OF EXTRACORPOREAL MEMBRANE |
| EP3594230A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
| US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| EP3016729B1 (fr) | 2013-07-05 | 2020-03-25 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Matrice de chromatographie d'affinité |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| EP3388140A1 (en) * | 2017-04-10 | 2018-10-17 | Gambro Lundia AB | Extracorporeal blood circuit |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4517294A (en) | 1982-03-03 | 1985-05-14 | Genentech, Inc. | Human antithrombin III |
| US4632981A (en) | 1982-07-30 | 1986-12-30 | Genentech, Inc. | Human antithrombin III |
| US6727405B1 (en) | 1986-04-09 | 2004-04-27 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
| DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US5366894A (en) | 1986-06-30 | 1994-11-22 | Pharmaceutical Proteins Limited | Peptide production |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5439446A (en) | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
| DE4028800A1 (de) | 1990-09-11 | 1992-03-12 | Behringwerke Ag | Gentechnische sialylierung von glykoproteinen |
| DE4326665C2 (de) | 1993-08-09 | 1995-07-13 | Biotest Pharma Gmbh | Verfahren zur Sterilfiltration von Milch |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5843705A (en) * | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| US5801063A (en) | 1995-05-09 | 1998-09-01 | Grandics; Peter | Device and process for the biospecific removal of heparin |
| US6268487B1 (en) | 1996-05-13 | 2001-07-31 | Genzyme Transgenics Corporation | Purification of biologically active peptides from milk |
| CA2281949A1 (en) | 1997-02-25 | 1998-08-27 | Genzyme Transgenics Corporation | Transgenically produced non-secreted proteins |
| US20060264357A1 (en) * | 1997-04-22 | 2006-11-23 | Zikria Bashir A | Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals |
| US8257724B2 (en) | 1998-09-24 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
| DE10159556A1 (de) | 2001-12-05 | 2003-06-12 | Aventis Behring Gmbh Intellect | Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen |
| SE521676C2 (sv) | 2002-01-02 | 2003-11-25 | Dilafor Ab | Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US7191068B2 (en) | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
| CA2537273A1 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| CA2479968A1 (en) | 2004-09-01 | 2006-03-01 | Keith R. Walley | Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome |
| EP1776108A1 (en) | 2004-06-23 | 2007-04-25 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| US20090148458A1 (en) | 2005-06-23 | 2009-06-11 | The University Of British Columbia | Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy |
| WO2007014244A2 (en) | 2005-07-25 | 2007-02-01 | Gtc Biotherapeutics, Inc. | Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile |
| KR20140133958A (ko) | 2005-10-21 | 2014-11-20 | 엘에프비 유에스에이, 인크. | 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법 |
| US20070292407A1 (en) | 2005-12-12 | 2007-12-20 | The Board Of Trustees Operating Michigan State University | Methods of treatment for meconium aspiration syndrome |
| US7531632B2 (en) | 2006-02-16 | 2009-05-12 | Gtc Biotherapeutics, Inc. | Clarification of transgenic milk using depth filtration |
| US8173860B2 (en) | 2006-04-21 | 2012-05-08 | Gtc Biotherapeutics, Inc. | Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion |
| WO2009097584A1 (en) | 2008-01-30 | 2009-08-06 | Proteogenix, Inc. | Maternal serum biomarkers for detection of pre-eclampsia |
| US20110082083A1 (en) | 2009-04-10 | 2011-04-07 | Gtc Biotherapeutics, Inc. | Formulations of liquid stable antithrombin |
| US8551096B2 (en) | 2009-05-13 | 2013-10-08 | Boston Scientific Scimed, Inc. | Directional delivery of energy and bioactives |
| EP2729164A4 (en) | 2011-07-07 | 2015-05-06 | Lfb Usa Inc | FORMULATIONS STABILIZING PROTEINS |
| TW201400499A (zh) | 2012-03-12 | 2014-01-01 | Revo Biolog Inc | 抗凝血酶用於治療妊娠毒血症之用途 |
| EP2879697A4 (en) | 2012-08-03 | 2016-01-20 | Lfb Usa Inc | USE OF ANTITHROMBIN IN OXYGENATION OF EXTRACORPOREAL MEMBRANE |
-
2013
- 2013-08-02 EP EP13825397.6A patent/EP2879697A4/en not_active Withdrawn
- 2013-08-02 AU AU2013296240A patent/AU2013296240B2/en not_active Ceased
- 2013-08-02 AR ARP130102756A patent/AR091977A1/es unknown
- 2013-08-02 US US14/239,943 patent/US9511087B2/en not_active Expired - Fee Related
- 2013-08-02 CN CN201380041286.1A patent/CN104884080A/zh active Pending
- 2013-08-02 CA CA2879763A patent/CA2879763C/en active Active
- 2013-08-02 WO PCT/US2013/053365 patent/WO2014022748A1/en not_active Ceased
- 2013-08-02 TW TW102127828A patent/TW201425332A/zh unknown
- 2013-08-02 BR BR112015002321A patent/BR112015002321A2/pt not_active IP Right Cessation
- 2013-08-02 KR KR1020157002667A patent/KR20150039201A/ko not_active Ceased
- 2013-08-02 MX MX2015001508A patent/MX2015001508A/es unknown
- 2013-08-02 JP JP2015525617A patent/JP6389172B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-18 IL IL236776A patent/IL236776A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL236776A0 (en) | 2015-03-31 |
| US20140194360A1 (en) | 2014-07-10 |
| WO2014022748A1 (en) | 2014-02-06 |
| JP2015524823A (ja) | 2015-08-27 |
| CA2879763A1 (en) | 2014-02-06 |
| CN104884080A (zh) | 2015-09-02 |
| BR112015002321A2 (pt) | 2019-10-22 |
| CA2879763C (en) | 2020-12-01 |
| AU2013296240A1 (en) | 2015-02-12 |
| JP6389172B2 (ja) | 2018-09-12 |
| TW201425332A (zh) | 2014-07-01 |
| EP2879697A1 (en) | 2015-06-10 |
| AU2013296240B2 (en) | 2018-05-17 |
| US9511087B2 (en) | 2016-12-06 |
| KR20150039201A (ko) | 2015-04-09 |
| AR091977A1 (es) | 2015-03-11 |
| EP2879697A4 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015001508A (es) | El uso de antitrombina en la oxigenacion por membrana extracorporea. | |
| BR112015012014A2 (pt) | proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb) | |
| WO2011106376A3 (en) | Use of microvesicles in the treatment of medical conditions | |
| MX2017010734A (es) | Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos. | |
| MY174894A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| PH12015500561A1 (en) | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | |
| MX2021001867A (es) | Administracion y monitoreo de oxidio nitrico en fluidos ex vivo. | |
| EA201170465A1 (ru) | Способы лечения прогрессирующего множественного склероза | |
| MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
| WO2010091376A3 (en) | Devices and methods for perfusion therapy | |
| PL2563403T3 (pl) | Koniugat czynnika krzepnięcia krwii viia i peg | |
| EP4488289A3 (en) | Long-acting coagulation factors and uses thereof | |
| ZA201402745B (en) | Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and the use thereof. | |
| IN2014CN04861A (https=) | ||
| WO2012053823A3 (ko) | 인자 ix 활성을 갖는 융합 단백질 | |
| MX344189B (es) | Formulaciones de mazindol. | |
| WO2011163512A3 (en) | Cancer therapy | |
| EA201390925A1 (ru) | Производные санглиферина и способы их получения | |
| MX2013009456A (es) | Compuestos de azufre aromaticos sustituidos y metodos para su uso. | |
| MX2012012930A (es) | Composicion farmaceutica topica que comprende heparina. | |
| MX2013012551A (es) | Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares. | |
| WO2012135746A3 (en) | Methods and devices comprising extracorporeal blood flow | |
| UA97741C2 (ru) | Способ восстановления кожных покровов при глубоких распространенных ожогах микроаутодермотрансплантатами | |
| JO3333B1 (ar) | استعمال 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium أو ملح مقبول دوائيا منه للوقاية من السكري وعلاجه | |
| UA65220U (ru) | Способ гемостаза при проведении хирургического вмешательства на щитовидной железе |